Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 6 trials

Late-Stage Pipeline

67%

4 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results

Data Visualizations

Phase Distribution

4Total
P 3 (4)

Trial Status

Recruiting3
Active Not Recruiting3

Clinical Trials (6)

Showing 6 of 6 trials
NCT04994132Phase 3Active Not Recruiting

A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma

NCT05304585Phase 3RecruitingPrimary

Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma

NCT02567435Phase 3Active Not Recruiting

Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

NCT03296371Active Not Recruiting

Genetic Mutational Analysis of Saliva or Buccal Mucosa Samples From Patients With Embryonal or Alveolar Rhabdomyosarcoma

NCT03382158Recruiting

International PPB/DICER1 Registry

NCT06669013Phase 3Recruiting

Chemo-immunotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue Sarcomas

Showing all 6 trials

Research Network

Activity Timeline